Advertisement


Paul Sargos, MD, on Prostate Cancer: Adjuvant or Early Salvage Radiotherapy Plus Androgen Deprivation

2020 ASTRO Annual Meeting

Advertisement

Paul Sargos, MD, of the Institut Bergonié, discusses phase III findings from the GETUG-AFU 17 study, which compared adjuvant vs early salvage radiotherapy, both combined with short-term androgen-deprivation therapy after radical prostatectomy for localized prostate cancer. Although lacking statistical power, the study showed no benefit in event-free survival for adjuvant compared to salvage radiotherapy (Abstract 33).



Related Videos

Prostate Cancer

Justin Oh, MD, on Prostate Cancer: Brachytherapy vs External-Beam Radiation Therapy

Justin Oh, MD, of the University of British Columbia, discusses results from the ASCENDE-RT trial, which compared a low-dose–rate brachytherapy boost to a dose-escalated external-beam boost for patients with high- and intermediate-risk prostate cancers (Abstract 127).

CNS Cancers

Vinai Gondi, MD, on Glioblastoma: Dose Intensification, IMRT, Standard Radiotherapy, and Temozolomide

Vinai Gondi, MD, of Northwestern Medicine Cancer Center and Northwestern Medicine Proton Center, discusses the preliminary results of an NRG Oncology study of radiotherapy dose intensification using intensity-modulated radiotherapy vs standard-dose radiotherapy with temozolomide in patients with newly diagnosed glioblastoma (Abstract 42).

Prostate Cancer

Cynthia Menard, MD, on Prostate Cancer: PSMA PET- and CT-Guided Intensification of Radiotherapy

Cynthia Menard, MD, of the University of Montreal, discusses a study on the use of prostate-specific membrane antigen PET and CT to guide treatment. The scans led to high rates of new lesion detection and therefore intensification of radiotherapy for patients with prostate cancer, without an increase in side effects (Abstract 34).

Supportive Care
Pain Management

Arjun Sahgal, MD, on Reducing the Pain of Spinal Metastases: SBRT vs Palliative Radiotherapy

Arjun Sahgal, MD, of the Sunnybrook Health Sciences Centre, discusses results of the first phase III trial to suggest that dose escalation with stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving pain outcomes for patients with spinal bone metastases (Abstract LBA2).

CNS Cancers

Jeff M. Michalski, MD, MBA, on Medulloblastoma and Radiation Treatment in Pediatric Patients

Jeff M. Michalski, MD, MBA, of the Washington University School of Medicine, discusses a Children’s Oncology Group study that confirmed data previously reported: Involved-field radiotherapy is noninferior to posterior fossa radiotherapy in patients with average risk-medulloblastoma. However, low-dose craniospinal irradiation is not as effective as standard-dose irradiation in younger children (Abstract 1).

Advertisement

Advertisement



Advertisement